Abivax (ABVX) Shares Plunge Over 30% Following Update on Bowel Disease Drug Trial
Abivax is strategically planning to raise funds following the release of crucial trial data, indicating its intent to remain independent amid ongoing takeover speculation, which has significantly influenced its stock performance.